Opening | Keynotes 

Moderation:

• Deborah O’Neil, CEO, Novabiotics Ltd. & Board Member, BEAM Alliance

Speakers:

• David Barros-Aguirre, VP, Head of GSK Global Health Pharma R&D Unit, Tres Cantos, Spain
• Justin Yang, Director, Catalyst Office, BARDA, Division of Research Innovation and Ventures (DRIVe) & Founder of BARDA Ventures, US
• Janet Hemingway, Founding Director of the Infection Innovation Consortium (iiCON), UK

Panel discussion – What has changed in the fight against AMR after one year of COVID?

Speakers:

• all previous opening speakers
• Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, EMA

Spotlight on: AMR innovation during the pandemic – challenges and best-practices

Moderation:

• Jessica Boname, Head of Antimicrobial Resistance, Medical Research Council, UK & Member of the JPI AMR Management Board

Speakers:

• Christoph Dehio, Professor of Molecular Microbiology at University of Basel, Switzerland & Director of NCCR AntiResist
• Jürgen Popp, Chair for Physical Chemistry, Friedrich-Schiller University Jena & Scientific director of Leibniz Institute of Photonic Technology, Jena, Germany
• Philippe Villain-Guillot, CEO & Co-founder, Nosopharm, France

Panel discussion:
Infectious diseases in the spotlight – How investors evaluate AMR innovation

Moderation:

• Marc Gitzinger, CEO, Bioversys, Switzerland & Vice-President, BEAM Alliance

Speakers:

• Aleks Engel, Partner, Novo Holding & Director, REPAIR Impact Fund (for more information, see the speaker interview here)
• David P. Luci, President, CEO & Co-founder, Acurx Pharmaceuticals, Inc., US
• Henry Skinner, CEO, AMR Action Fund

Focus on incubators and public-private accelerators in US and Europe – How they drive the AMR innovation pipeline

Moderation:

• Peter Jackson, Executive director, Infex Therapeutics

Speakers:

• Anders Karlén, Professor in Computer-Aided Drug Design, Uppsala University, Sweden & Coordination team of the IMI AMR Accelerator 
• Erin Duffy, Chief of Research & Development, CARB-X, US
• Douglas Häggström, Community Manager INCATE,
  Innovation Office, University of Basel, Switzerland
• Igor Orshanskiy, Director Business Development & Licensing, External Innovations & Alliances, AiCuris Anti-infective Cures, Germany 

Keynotes | Panel

What can we expect and learn from the US and UK pull incentive initiatives?

Moderation:

• Kathy Talkington, Director Public Health, PEW Health Charitable Trusts, US

Speakers:

• Enrico Baraldi, Professor of Industrial Engineering & Manager of PLATINEA, University of Uppsala, Sweden & Caline Mattar, Assistant Professor of Medicine, Washington University in St Louis, US
• Colm Leonard, Consultant Clinical Adviser, NICE, UK & David Glover, Deputy Head of the Medicines Analysis Team, NHS England, UK
• Kevin Outterson, Professor of Law & Executive Director, CARB-X, US

Outlook: How to further drive pull incentives on the policy agenda

Moderation:

• Peter Beyer, Unit Head, Impact Initiatives and Research Coordination, AMR Division, WHO
  

Speakers:

• Mark Jones, Head of Project Management Office, Basilea, Switzerland & Board Member, BEAM Alliance
• Thomas Cueni, Director General, IFPMA
• Isabelle Bekeredjian-Ding, Head of Microbiology Division at Paul-Ehrlich-Institut (PEI), Germany
• Greg Frank, Director Global Public Policy, MSD & AMR Industry Alliance Representative
• Jeremy Knox, Policy and Advocacy Lead, Drug-Resistant Infections Programme, Wellcome Trust